Ameriprise’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.68M | Sell |
200,352
-47,015
| -19% | -$494K | ﹤0.01% | 3037 |
|
|
2025
Q4 | $3.56M | Buy |
247,367
+5,289
| +2% | +$65.9K | ﹤0.01% | 2679 |
|
|
2025
Q3 | $2.34M | Sell |
242,078
-130,771
| -35% | -$1.16M | ﹤0.01% | 2931 |
|
|
2025
Q2 | $3.06M | Buy |
372,849
+41,958
| +13% | +$351K | ﹤0.01% | 2703 |
|
|
2025
Q1 | $2.37M | Buy |
330,891
+46,370
| +16% | +$345K | ﹤0.01% | 2811 |
|
|
2024
Q4 | $2.2M | Buy |
284,521
+12,883
| +5% | +$121K | ﹤0.01% | 2874 |
|
|
2024
Q3 | $2.85M | Sell |
271,638
-3,164
| -1% | -$38.6K | ﹤0.01% | 2726 |
|
|
2024
Q2 | $3.22M | Buy |
274,802
+4,161
| +2% | +$64.8K | ﹤0.01% | 2613 |
|
|
2024
Q1 | $5.7M | Sell |
270,641
-106,087
| -28% | -$1.89M | ﹤0.01% | 2270 |
|
|
2023
Q4 | $6.76M | Buy |
376,728
+117,060
| +45% | +$2.06M | ﹤0.01% | 2116 |
|
|
2023
Q3 | $4.27M | Sell |
259,668
-5,902
| -2% | -$107K | ﹤0.01% | 2404 |
|
|
2023
Q2 | $5.31M | Sell |
265,570
-27,938
| -10% | -$538K | ﹤0.01% | 2302 |
|
|
2023
Q1 | $5.55M | Buy |
293,508
+74,523
| +34% | +$1.65M | ﹤0.01% | 2245 |
|
|
2022
Q4 | $4.96M | Sell |
218,985
-6,388
| -3% | -$144K | ﹤0.01% | 2304 |
|
|
2022
Q3 | $5.96M | Sell |
225,373
-7,885
| -3% | -$234K | ﹤0.01% | 2086 |
|
|
2022
Q2 | $5.76M | Sell |
233,258
-2,744
| -1% | -$68.6K | ﹤0.01% | 2173 |
|
|
2022
Q1 | $7.83M | Buy |
236,002
+307
| +0.1% | +$8.53K | ﹤0.01% | 2103 |
|
|
2021
Q4 | $7.71M | Buy |
235,695
+14,991
| +7% | +$510K | ﹤0.01% | 2174 |
|
|
2021
Q3 | $9.25M | Buy |
220,704
+17,425
| +9% | +$627K | ﹤0.01% | 1914 |
|
|
2021
Q2 | $7.9M | Sell |
203,279
-2,617
| -1% | -$93.6K | ﹤0.01% | 2116 |
|
|
2021
Q1 | $7.02M | Buy |
205,896
+25,925
| +14% | +$1.11M | ﹤0.01% | 2159 |
|
|
2020
Q4 | $8.16M | Sell |
179,971
-21,046
| -10% | -$735K | ﹤0.01% | 1901 |
|
|
2020
Q3 | $5.53M | Sell |
201,017
-30,726
| -13% | -$1M | ﹤0.01% | 2005 |
|
|
2020
Q2 | $8.54M | Sell |
231,743
-20,595
| -8% | -$768K | ﹤0.01% | 1650 |
|
|
2020
Q1 | $8.17M | Buy |
252,338
+2,868
| +1% | +$119K | ﹤0.01% | 1543 |
|
|
2019
Q4 | $10.2M | Buy |
249,470
+831
| +0.3% | +$32.8K | ﹤0.01% | 1734 |
|
|
2019
Q3 | $8.85M | Sell |
248,639
-640
| -0.3% | -$25.9K | ﹤0.01% | 1799 |
|
|
2019
Q2 | $12.8M | Sell |
249,279
-33,462
| -12% | -$1.67M | 0.01% | 1532 |
|
|
2019
Q1 | $16.2M | Buy |
282,741
+24,502
| +9% | +$1.21M | 0.01% | 1289 |
|
|
2018
Q4 | $10.8M | Buy |
258,239
+49,620
| +24% | +$2.91M | 0.01% | 1534 |
|
|
2018
Q3 | $15.8M | Buy |
208,619
+16,511
| +9% | +$1.19M | 0.01% | 1504 |
|
|
2018
Q2 | $13.8M | Buy |
+192,108
| New | +$9.17M | 0.01% | 1468 |
|
|
2017
Q3 | – | Sell |
-51,804
| Closed | -$1.02M | – | 3748 |
|
|
2017
Q2 | $1.02M | Sell |
51,804
-359
| -0.7% | -$6.95K | ﹤0.01% | 2930 |
|
|
2017
Q1 | $1.01M | Sell |
52,163
-3,645
| -7% | -$70.3K | ﹤0.01% | 2886 |
|
|
2016
Q4 | $1.03M | Buy |
+55,808
| New | +$1.07M | ﹤0.01% | 2959 |
|
|
2015
Q4 | – | Sell |
-37,701
| Closed | -$832K | – | 3927 |
|
|
2015
Q3 | $832K | Buy |
+37,701
| New | +$962K | ﹤0.01% | 3056 |
|
Other funds holding RGNX
RG
VCM
IHAM
Ameriprise's RGNX Position: Q1 2026 in Review
Ameriprise reduced its Regenxbio (RGNX) stake by 19% in Q1 2026, selling an estimated $494K and leaving 200,352 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #3037.
Ameriprise first reported a position in RGNX in Q3 2015 and has held it in 36 quarters since. The position peaked at $16.2M in Q1 2019. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.
- Ameriprise held 200,352 shares of Regenxbio worth $1.68M as of Q1 2026.
- Ameriprise sold 47,015 Regenxbio shares in Q1 2026, an estimated $494K.
- Regenxbio made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3037 holding.
- Ameriprise first reported a position in Regenxbio in Q3 2015 and has held it in 36 quarters since.
- Ameriprise's Regenxbio position peaked at $16.2M in Q1 2019.
- 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.
Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.